Literature DB >> 19284382

Tumor suppressor genes in myeloid differentiation and leukemogenesis.

Christian Britschgi1, Martin F Fey.   

Abstract

Tumor suppressor genes, such as p53, RB, the INK4-ARF family and PML, suppress malignant transformation by regulating cell cycle progression, ensuring the fidelity of DNA replication and chromosomal segregation, or by inducing apoptosis in response to potentially deleterious events. In myeloid leukemia, hematopoietic differentiation resulting from highly coordinated, stage-wise expression of myeloid transcription and soluble signaling factors is disrupted leading to a block in terminal differentiation and uncontrolled proliferation. This virtually always involves functional inactivation or genetic disruption of one or several tumor suppressor genes in order to circumvent their checkpoint control and apoptosis-inducing functions. Hence, reactivation of tumor suppressor gene function has therapeutic potential and can possibly enhance conventional cytotoxic chemotherapy. In this review, we focus on the role of different tumor suppressor genes in myeloid differentiation and leukemogenesis, and discuss implications for therapy.

Entities:  

Mesh:

Year:  2009        PMID: 19284382     DOI: 10.2217/14796694.5.2.245

Source DB:  PubMed          Journal:  Future Oncol        ISSN: 1479-6694            Impact factor:   3.404


  3 in total

1.  Transcription suppression of SARI (suppressor of AP-1, regulated by IFN) by BCR-ABL in human leukemia cells.

Authors:  Qing Huang; Yan Yang; Xiaoqing Li; Shiang Huang
Journal:  Tumour Biol       Date:  2011-09-03

2.  Decreased SARI expression predicts poor prognosis of Chinese patients with non-small cell lung cancer.

Authors:  Ren-Jie Zhou; Zhong Shi; Kun Zhou; Hai-Dong Wang; Guo-Qiang Zhang; Xue-Tao Li; Jian-Ping Xu
Journal:  Int J Clin Exp Pathol       Date:  2013-09-15

Review 3.  Targeting mTOR for the treatment of AML. New agents and new directions.

Authors:  Jessica K Altman; Antonella Sassano; Leonidas C Platanias
Journal:  Oncotarget       Date:  2011-06
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.